

Table S1**Antiproliferative activity of pazopanib in human synovial sarcoma cell lines**

Cell line	Fusion transcript	pazopanib IC₅₀ [μM]^a	hours of treatment
SYO-1	SS18-SSX2	0.6± 0.1	72
CME-1	SS18-SSX2	3 ± 0.29	72
MoJo	SS18-SSX1	13 ± 3	96
Aska-SS	SS18-SSX1	5 ± 1.2	96
Yamato-SS	SS18-SSX1	> 15	96
1273/99	SS18-SSX2	> 15	96

^a IC₅₀, drug concentration producing 50% inhibition, determined by cell counting after 72h or 96h of treatment, according to the cells' growth rate.